预约演示

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs

2023-09-27

交易

临床2期临床3期

Roche's most advanced attempts to treat both diseases have struggled in the clinic.

RocheRoche’s gantenerumab failed a pair of phase 3 studies last year, the pharma giant said it would look for “external collaborations and partnerships” as an avenue to treat Alzheimer’s disease. With today’s agreement with longtime partner Ionis, it seems the drugmaker is sticking to its word.

The SRochephagantenerumabg $60 million upfront for the exclusive worldwide rights to two undisclosed, preclinical RNA-targeting programs in the notoriously tricky indications Alzheimer’s diseaseHuntington’s diseases.Ionis

Ionis will take the programs through preclinical studies before Roche takes over sole responsibility for human trials and potentially commercialization.

Ionisll as the upfront cash, the Big Pharma agreed to pay develoRoche, regulatory and commercial milestones. But the companies are keeping the amount of biobucks at stake under wraps.

"Our lasting partnership with Ionis, a leader in RNA-targeted therapeutics, is a great example of two collaborators mutually benefiting from their relationship by complementing and learning from each other," James Sabry, Ph.D., global head of Roche Pharma Partnering, said in this morning’s release.

"By expanding our alliance, weIonisg together the companies' combined knowledge of the science in Alzheimer's disease and Huntington's disease with Roche's proven capabilities in the development and commercialization of innovative treatments iRoche Pharma Partneringadded.

Roche has already been burned attempting to treat both diseases. Its major Alzheimer’s contender, Alzheimer's diseased to Huntington's diseased funcRochel decline in the two much-anticipated trials from the GRADUATE program in November of last year, leading the Big Pharma to cut most of the program.

However, Roche does have a number of other potential Alzheimer’s therapies in its pipeline, includgantenerumabmmune-partnered anti-amyloid-beta antibody called crenezumab, which has also come up short in the clinic.

Keeping iRochepany in phase 2 are the UCB-partnered anti-tau antibody bepranemab, the AC Immune-partnered AC Immuneantibody semorinemab and a different formulatcrenezumabtenerumab called trontinemab.

Unlike those antibody therapies, todayUCBIonis alliaanti-tau antibodyobepranemabdd an RNA approach to its Alzheimer’s portfosemorinemab gantenerumab trontinemab

It’s not the company’s first push into this area, however. In Roche the Big Pharma signed a pact with Shape Therapeutics to use its RNA-editing platform to explore next-generation gene therapies for Alzheimer’s, Parkinson’s and rare diseases.

When it comes to Huntington’s, Roche and Ionis have previous experience due to their collaboration on Shape Therapeutics past decade. The partners have pressed ahead with a phase 2 trial of the antisense drug in a subgroup of patients despite a late-stage study providing to be one of the highest profile flops of 2021.

“Collaborating on these two proRoche enables Ionis to advance our wholly owned programs, including those in neurology, aligned with our strategic priorities,” Ionis CEO CEO Brett Monia, Ph.D., added in today’s release.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构